Home › Schizophrenia › NCT07680946

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Evaluating Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Who can join

Ages 18 to 60 · All sexes

Inclusion Criteria:

1. Primary diagnosis of schizophrenia.
2. Treatment-resistant.
3. Requires antipsychotic treatment and is currently receiving "standard of care".
4. PANSS total score between 80 and 120, inclusive at screening and baseline.

Exclusion Criteria

1. Any primary Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) disorder other than schizophrenia.
2. Ongoing clozapine treatment.
3. Risk for suicidal behavior.
4. Any severe or uncontrolled medical condition that could affect the participant's ability to participate.

Note: Other protocol-specified Inclusion/Exclusion criteria may apply

About the study

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.

What is being tested

• Ublituximab (drug)

Sponsor: TG Therapeutics, Inc. · Participants: 60 · Started: Jul 27, 2026

Contact the study team

• TG Therapeutics Clinical Support Team · Phone: 1-877-575-8489

Official record on ClinicalTrials.gov — NCT07680946

Locations in the U.S.

Conditions

• Schizophrenia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.